• 455
    0

    Besponsa (inotuzumab ozogamicin) is a CD22-directed antibody-drug conjugate (ADC). Besponsa is specifically indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Besponsa is supplied as a solution for intravenous injection. The recommended dose schedule is as follows: For the first cycle: the recommended total dose of Besponsa for all patients ...